Neurogene (NGNE) Set to Announce Earnings on Thursday

Neurogene (NASDAQ:NGNE) is expected to release its Q3 2026 resultson Thursday, November 12th. Analysts expect Neurogene to post earnings of ($1.49) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). On average, analysts expect Neurogene to post ($5.88) EPS for the current fiscal year and ($6.23) EPS for the next fiscal year.

Neurogene Stock Performance

NASDAQ NGNE opened at $27.58 on Thursday. The company’s fifty day moving average is $29.97 and its two-hundred day moving average is $27.86. Neurogene has a 52-week low of $15.93 and a 52-week high of $43.66.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NGNE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Neurogene in a research note on Wednesday, October 28th. JPMorgan Chase & Co. assumed coverage on Neurogene in a report on Thursday, October 8th. They issued an “overweight” rating and a $60.00 price target for the company. William Blair raised Neurogene to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Guggenheim raised their price objective on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $80.29.

Neurogene Company Profile

Neurogene Inc (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.

Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis.